Innate immune activation of astrocytes impairs neurodevelopment via upregulation of follistatin-like 1 and interferon-induced transmembrane protein 3

Shinnosuke Yamada¹, Norimichi Itoh¹, Taku Nagai¹, Tsuyoshi Nakai¹, Daisuke Ibi², Akira Nakajima³, Toshitaka Nabeshima⁴ and Kiyofumi Yamada¹*

Abstract

Background: Polyriboinosinic-polyribocytidylic acid (polyI:C) triggers a strong innate immune response that mimics immune activation by viral infections. Induction of interferon-induced transmembrane protein 3 (Ifitm3) in astrocytes has a crucial role in polyI:C-induced neurodevelopmental abnormalities. Through a quantitative proteomic screen, we previously identified candidate astroglial factors, such as matrix metalloproteinase-3 (Mmp3) and follistatin-like 1 (Fstl1), in polyI:C-induced neurodevelopmental impairment. Here, we characterized the Ifitm3-dependent inflammatory processes focusing on astrocyte-derived Fstl1 following polyI:C treatment to assess the neuropathologic role of Fstl1.

Methods: Astrocytes were treated with PBS (control) or polyI:C (10 μg/mL). The conditioned medium was collected 24 h after the polyI:C treatment and used as astrocyte condition medium (ACM). The expression of Fstl1 mRNA and extracellular Fstl1 protein levels were analyzed by quantitative PCR and western blotting, respectively. For functional studies, neurons were treated with ACM and the effects of ACM on dendritic elongation were assayed. To examine the role of Fstl1, recombinant Fstl1 protein and siRNA for Fstl1 were used. To investigate the expression of Fstl1 in vivo, neonatal mice were treated with vehicle or polyI:C on postnatal day 2 to 6.

Results: ACM prepared with polyI:C (polyI:C ACM) contained significantly higher Fstl1 protein than control ACM, but no increase in Fstl1 was observed in polyI:C ACM derived from Ifitm3-deficient astrocytes. We found that the production of Fstl1 involves the inflammatory responsive molecule Ifitm3 in astrocytes and influences neuronal differentiation. In agreement, the levels of Fstl1 increased in the hippocampus of polyI:C-treated neonatal mice. COS7 cells co-transfected with both Fstl1 and Ifitm3 had higher extracellular levels of Fstl1 than the cells transfected with Fstl1 alone. Treatment of primary cultured hippocampal neurons with recombinant Fstl1 impaired dendritic elongation, and the deleterious effect of polyI:C ACM on dendritic elongation was attenuated by knockdown of Fstl1 in astrocytes.

Conclusions: The extracellular level of Fstl1 is regulated by Ifitm3 in astrocytes, which could be involved in polyI:C-induced neurodevelopmental impairment.

Keywords: Astrocyte, Fstl1, Ifitm3, Immune response, Neuron, polyI:C, Schizophrenia, Viral infection

* Correspondence: kyamada@med.nagoya-u.ac.jp
† Shinnosuke Yamada, Norimichi Itoh and Taku Nagai contributed equally to this work.
1Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Turumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Immune activation in the CNS is associated with the pathophysiology and/or etiology of psychiatric disorders. For example, inflammatory cytokine levels are altered in the serum of schizophrenia patients [1, 2]. Pro- and anti-inflammatory cytokines in patients with major depressive disorders are inversely correlated with severity and symptoms of major depression [3]. Epidemiological evidence also indicates that the risk of schizophrenia increases in offspring born from mothers infected during pregnancy [4–6]. Although much evidence suggests that reactive astrocytes induced by inflammatory cytokines are involved in neurodevelopmental disorders [7, 8], the underlying molecular mechanism is largely unknown.

Interferon-induced transmembrane protein 3 (Ifitm3) is induced by inflammatory cytokines such as interferon-β, interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Ifitm3 acts as an antiviral factor by restricting virus entry [9–12]. Recent studies have indicated that Ifitm3 expression is increased in patients with schizophrenia [13–15]. Previously, we have reported that Ifitm3 expression in astrocytes is associated with neurodevelopmental impairment and contributes to brain dysfunction in mice that received daily polyI:C injection from postnatal day 2 to day 6 [16]. We also found that humoral factors released from polyI:C-treated astrocytes have crucial roles in Ifitm3-dependent impairment of neuronal maturation of cultured neurons [17]. For instance, matrix metalloprotease-3 (Mmp3) is released by polyI:C-treated astrocytes and impairs neuronal maturation [18]. In addition to Mmp3, we have identified several candidates of humoral factors including follistatin-like-1 (Fstl1) by proteomic analysis [18].

To investigate the regulation of Fstl1 production and release, we monitored extracellular levels of Fstl1 protein in astrocyte cultures, which were stimulated with polyI:C or prepared from Ifitm3 knockout (KO) mice. We found that an immune activation induced by polyI:C upregulates Fstl1 mRNA expression in astrocytes, and that polyI:C-treated astrocytes have increased extracellular protein levels of Fstl1. Notably, in astrocytes from Ifitm3 KO mice, polyI:C treatment failed to increase the extracellular Fstl1 level. We also demonstrated that recombinant Fstl1 impaired dendritic neurite outgrowth of cultured hippocampal neurons, but knockdown of Fstl1 partially rescued polyI:C-induced impairment of neurite elongation. These results suggest that Fstl1 has an important role in Ifitm3-dependent neuronal impairment.

Methods
Animals
C57BL/6 mice were purchased from Japan SLC Inc. (Hamamatsu, Japan). Homozygous Ifitm3−/− [Ifitm3 KO] mice were generated and characterized as described previously [19]. The animals had free access to food (CE-2, Clea Japan, Tokyo, Japan) and water and were kept under controlled conditions (23 ± 1 °C) with a constant light-dark cycle (light 9:00–21:00). All animals were handled in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Nagoya University, the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society, and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Astrocyte culture and astrocyte-conditioned medium (ACM) preparation
Secondary astrocyte cultures were prepared as described previously [18]. Briefly, cortices and hippocampi of neonatal mice at postnatal day (PD) 1–2 were mechanically dissociated and digested with 0.3% dispase (Roche Diagnostics GmbH, Mannheim, Germany) and 0.4% DNase (Roche Diagnostics GmbH). The cells were suspended in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO) containing 10% fetal bovine serum (FBS, Gibco-BRL, Gaithersburg, MD) and filtered through a 40 μm nylon cell strainer (Falcon-Becton Dickinson, Le Pont de Claix, France). The cell suspension was cultured in a T150 flask at a density of 500000 cells per flask at 37 °C with 5% CO2. Confluent primary astrocyte cultures were purified by shaking, plated onto 6-well plates, and grown to confluence in all experiments. Under these conditions, more than 95% of cells were glial fibrillary acidic protein (GFAP)-positive (a marker for astrocytes) and negative for tau/MAP2 and CD11b (neuronal and microglial markers, respectively). Culture medium was modified Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO) supplemented with B-27 (Invitrogen, Eugene, OR) supplemented with B-27 (Invitrogen) and 1 mM glutamine (Sigma-Aldrich) 6 days before treatment with polyI:C (Sigma-Aldrich). This medium was replaced 3 days before and 24 h before treatment with polyI:C. For western blotting, B-27 was excluded from the last medium. Astrocytes were treated with PBS (control) or polyI:C (10 μg/mL), and conditioned medium was collected 24 h after the polyI:C treatment. For the time course analysis, conditioned medium was collected 6 h and 12 h after polyI:C treatment. Conditioned media were centrifuged at 10000xg for 10 min at 4 °C, and the supernatants were used as ACM.

Microglia culture and microglia-conditioned medium (MCM) preparation
2 weeks after seeding primary astrocyte cultures, microglia were separated from the underlying astrocytic monolayer by shaking for 3 h at 150 rpm. The supernatants, including floating microglia, were centrifuged at 1000 rpm for 10 min and the pellet was resuspended in
fresh culture medium. Microglia were plated at 1 x 10^6 cells/well in a 6-well plate and culture medium was replaced with neurobasal medium supplemented with 1 mM glutamine 1 h after plating. The microglial cultures were > 98% pure as assessed by immunocytochemistry with an anti-Iba1 antibody (Wako, Osaka, Japan) in combination with an anti-GFAP antibody (Sigma-Aldrich) as markers for microglia and astrocytes, respectively. PBS (control) or polyI:C (10 μg/mL) were added 24 h after medium change, and conditioned media were collected 24 h after polyI:C treatment. Conditioned media were centrifuged at 1000 x g for 10 min at 4 °C, and the supernatants were used as MCM.

**Fstl1 and Ifitm3 transfection for COS7 cells**

Myc-tagged mouse Fstl1 expression vector was purchased from OriGene Technologies (Rockville, MD), and myc-tagged mouse Ifitm3 vector was generated as described previously [17]. Control (mock) vector was generated by the removal of cDNA sequence from the cloning site of the expression vector using the appropriate restriction enzyme, then blunt-ended and ligated. The day before transfection, trypsinized COS7 cells were plated at 40 x 10^4 cells per well (6-well plate). Each well was transfected with 1.25 μg myc-tagged mouse Ifitm3 and Fstl1 or control vectors using Lipofectamine LTX (Invitrogen) and Opti-MEM I Reduced Serum Medium (Invitrogen). 6 h after transfection, growth medium was replaced with 2 mL of MEM without FBS and antibiotics. Conditioned medium and cell lysate samples for western blotting were prepared 30 h after transfection as described in the “Astrocyte culture and astrocyte-conditioned medium (ACM) preparation” section. Recombinant mouse Fstl1 (rmFstl1) was prepared from conditioned medium after transfection of 2.5 μg myc-tagged mouse Fstl1 expression vector. 30 h after transfection, secreted Fstl1 was purified using c-myc tagged Protein Mild Purification Kit ver.2 (MBL, Nagoya, Japan) according to the manufacturer’s instructions. Protein concentration was determined using a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).

**Primary cultured neurons and ACM treatment**

Primary cultured hippocampal neurons were prepared from C57BL/6J mice on gestational day 15–16 as described previously [18]. Briefly, embryo hippocampi were trypsinized (with 0.25% trypsin and 0.01% DNase) followed by trituration and seeded on coverslips precoated with 0.1 mg/mL poly-D-lysine at a low density (1.0 x 10^4 cells/well in a 24-well plate). Cells were cultured in Neurobasal Medium with B-27 and 1 mM glutamine. The medium was replaced with polyI:C ACM or control ACM and supplemented with 0.75 μM cytosine β-D-arabinofuranoside (ara-C, Sigma-Aldrich) on DIV2. For functional studies, rmFstl1 was added to control ACM or culture medium (Neurobasal Medium supplemented with B-27 and 1 mM glutamine) at the final concentrations of 10 nM, 50 nM, 100 nM, or 300 nM on DIV2. The effects of ACM on dendritic elongation were assayed on DIV7. More than 99% pure neurons, as evaluated by anti-tau or anti-MAP2 immunostaining, were obtained from this preparation.

**Knockdown assay**

siRNA transfection was performed 6 h before the last medium change. Astrocytes were transfected with Stealth siRNA for Fstl1 (#1 sense: GCCCAGUUGUCUGC UAUCAAGCUAA, #1 antisense: UUAGCUUGUAUGCA GACAAUCGGGC; #2 sense: CCGAGCAAAGUACU UUAAGAGCUUU, #2 antisense: AAAGCUCUAAAGU ACUUGUCAGG) or Stealth RNAi siRNA negative control (control siRNA) using Lipofectamine RNAiMAX transfection reagent (all from Invitrogen).

**Western blotting**

ACM and MCM were concentrated using Vivaspin 2 Hydrosart 5000 MWCO (Sartorius Stedim Biotech GmbH). After removing the conditioned medium, the remaining cells were washed with ice-cold PBS and collected in lysis buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 50 mM NaF, 2 mM EDTA, 1% Triton X-100, 1 mM sodium orthovanadate, 0.1% SDS, 1% sodium deoxycholate and protease inhibitor cocktail (Sigma-Aldrich)]. Protein lysates were centrifuged at 15,000 x g for 20 min. ACM or cell lysates were denatured in Laemmli sample buffer containing 20% β-mercaptoethanol at 95 °C for 5 min. An equal amount of protein for each sample was separated by 10% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore). The membrane was blocked with detector block solution (KPL, Gaithersburg, MD). The membrane was incubated with goat anti-Fstl1 antibody (R&D Systems, Minneapolis, MN) or goat anti-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 4 °C overnight. After incubation with horseradish peroxidase-conjugated secondary anti-goat antibody (R&D Systems) for 2 h, the membrane was incubated with ECL prime western blotting detection reagents (GE Healthcare) and protein bands were detected using a luminescent image analyzer (Atto, Tokyo, Japan).

**Total RNA isolation and real-time RT-PCR**

After removing the conditioned medium, total RNA of astrocytes and microglia were prepared using RNeasy Mini Kit (Qiagen, Hilden, Germany) and converted into complementary DNA (cDNA) using the SuperScript III First-Strand Synthesis Kit (Invitrogen). Quantitative real-time PCR was performed on a 7300 Real-Time PCR.
C57BL/6J mice were administered with a daily subcutaneous injection of saline (control) or polyIC (5 mg/kg, Sigma-Aldrich) between PD2 and PD6. Immunohistochemistry was conducted as described previously [17]. Neonatal mice were deeply anesthetized with diethyl ether 24 h after the final polyIC treatment and perfused transcardially with saline, followed by 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4). The brains were removed and cryoprotected. 20-μm-thick coronal brain sections were cut on a cryostat and mounted on slides. The sections were denatured in a microwave oven in 0.01 M citrate buffer (pH 6.0). After blocking with 5% donkey and 5% goat serum/PBS, mouse anti-glial fibrillary acidic protein (GFAP, a marker for astrocytes, 1:1,000, Sigma-Aldrich) and rat anti-Fstl1 (1:100, R&D Systems) were added to the sections. After washing in PBS, goat anti-mouse Alexa Fluor (AF) 568 and anti-rabbit AF488 antibodies (1:1,000, Invitrogen) were added to the sections. The samples were observed using a confocal-laser scanning microscope (LSM 700 Axio Imager; Zeiss).

**System (Applied Biosystems, Foster City, CA) using Power SYBR Green Master Mix (Applied Biosystems) according to the manufacturer’s protocol. The primers used were as follows: forward, GCCTATGCTACTCCGTGAAGT and reverse, GCCTGGGCTCCAGTICAT for Ifitm3; forward, CACAGGGCAAGCAGAAAG and reverse, GTGCTCTGTGCTCTCTTTAGATCT for Fstl1; and forward, CGATGCCCTAGGGCTCTT and reverse, TGGATGCCACAGGATTCCA for β-actin used as an internal control. Real-time PCR reactions were conducted as follows: initial 2 min incubation at 50 °C and 10 min incubation at 95 °C, followed by 40 reaction cycles of 95 °C for 15 s and 60 °C for 1 min. Fluorescent signals were monitored at the extension step of 60 °C in each cycle. For each sample test, each PCR reaction had two replicates and the relative gene expression differences were quantified using the comparative Ct method (ΔΔCt).

**Immunocytochemistry**

Cells were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 20 min and then permeabilized with 0.1% Triton X-100 for 10 min. After incubation in blocking solution (1% goat and 1% donkey serum in PBS) for 30 min, mouse anti-tau (1:500, Santa Cruz Biotechnology) and rabbit anti-Map2 (1:1000, Millipore) antibodies diluted in blocking solution were added to the cells. After overnight incubation with primary antibodies at 4 °C, the cells were treated with goat anti-mouse Alexa Fluor (AF) 488 and anti-rabbit AF568 antibodies (1:1,000, Invitrogen) for 2 h at room temperature. The cells were mounted in fluorescence mounting medium (Dako, Glostrup, Denmark) and photographed under a fluorescence microscope (Zeiss, Jena, Germany) using AxioCam MRC5 (Zeiss).

**Dendritic elongation assay**

Dendritic elongation of cultured hippocampal neurons was analyzed in accordance with a previous study [18]. Axons were identified by double immunostaining in terms of tau-positive (axonal marker) and MAP2-negative (dendritic marker), and only MAP2-positive neurites were defined as dendrites. Neurons that clearly had tau- or MAP2-positive neurites were selected randomly by an expert researcher who was blinded to the experimental groups. Dendrites were traced automatically with the same configuration using NeuroLucida software (MicroBrightField, Williston, VT) and total dendritic length in a single neuron was calculated using Neuroexplorer (MicroBrightField). This assay was performed for three independent experiments.

**Immunohistochemistry (IHC) for polyIC-treated neonatal mice**

All litters from C57BL/6J mice were randomly divided into two groups: vehicle- and polyIC-treated. Neonatal C57BL/6J mice were administered with a daily treatment: ΔΔCt.

**Statistical analysis**

Data are shown as the mean ± SE. Differences between two groups were analyzed by two-tailed Student’s t test and the data distribution was tested for normality with Shapiro-Wilk test. One-way and two-way analyses of variance (ANOVA) followed by Bonferroni post hoc test was applied for differences in three or more groups.

**Results**

We previously reported that Fstl1 was a candidate molecule responsible for polyIC-induced neurodevelopmental impairment, and that depletion of Ifitm3 in astrocytes attenuated polyIC ACM-induced neurodevelopmental impairment [17, 18]. We compared changes in Fstl1 protein levels between WT and Ifitm3 KO astrocytes after polyIC treatment (Fig. 1a). Two-way ANOVA revealed significant main effects of polyIC treatment on Fstl1 protein levels in both cell lysates (polyIC treatment: F(1,8) = 28.80, p < 0.01; genotype: F(1,8) = 0.22, p = 0.65; interaction of polyIC treatment and genotype: F(1,8) = 0.01, p = 0.94, Fig. 1b) and ACM (polyIC treatment: F(1,8) = 66.09, p < 0.01; genotype: F(1,8) = 37.21, p < 0.01); with an interaction of polyIC treatment and genotype: F(1,8) = 23.77, p < 0.01, Fig. 1c). PolyIC treatment significantly increased Fstl1 protein levels in the cell lysates of both WT and Ifitm3 KO astrocytes (p < 0.05) (Fig. 1b). Notably, polyIC treatment significantly increased Fstl1 levels in ACM from WT astrocytes but had no effect on extracellular Fstl1 levels in ACM from Ifitm3 KO astrocytes (Fig. 1c). To examine the influence of Ifitm3 expression on extracellular Fstl1 levels, COS7 cells were co-transfected with Fstl1 and Ifitm3. Fstl1 in COS7 cell lysates was not affected by...
overexpression of Ifitm3. On the other hand, Fstl1 levels in conditioned medium (CM) from COS7 cells co-transfected with Fstl1 and Ifitm3 were markedly higher than the levels from Fstl1 alone transfection ($p < 0.05$, Fig. 1d). These results suggest that the Fstl1 release is regulated by Ifitm3.

Because microglia are immunocompetent cells in the CNS, it is possible that microglia also play a similar role in the polyI:C-triggered glial inflammatory response. Accordingly, we examined the mRNA expression of Fstl1 and Ifitm3 in astrocytes and microglia. A two-way ANOVA revealed significant effects of polyI:C treatment on Ifitm3 mRNA levels in astrocyte and microglia cell lysates (polyI:C treatment: $F(1,12) = 188.0$, $p < 0.01$; cell type: $F(1,12) = 19.91$, $p < 0.01$; interaction of polyI:C treatment and cell type: $F(1,12) = 0.36$, $p = 0.56$, Fig. 2a). In contrast, there were significant interactions between cell type and polyI:C treatment on Fstl1 mRNA levels (polyI:C treatment: $F(1,12) = 25.84$, $p < 0.01$; cell type: $F(1,12) = 127.8$, $p < 0.01$; interaction of polyI:C treatment and cell type: $F(1,12) = 28.04$, $p < 0.01$, Fig. 2b). A multiple-comparison test with Bonferroni post hoc tests indicated that polyI:C treatment induced the expression of Fstl1 mRNA in COS7 cell lysates. Data show the mean ± SE ($n = 3$). *$p < 0.05$, and **$p < 0.01$ versus the respective control treatment.

**Fig. 1** Ifitm3 regulates the extracellular level of Fstl1. a Representative western blot images of Fstl1 protein expression in cell lysates and ACM derived from WT and Ifitm3 KO astrocytes 24 h after polyI:C treatment. b, c Fstl1 protein levels in cell lysates (b) and ACM (c) derived from WT and Ifitm3 KO astrocytes after polyI:C treatment. Values indicate the means ± SE ($n = 3$). *$p < 0.05$, and **$p < 0.01$ versus the respective control treatment. d The extracellular level of Fstl1 in conditioned medium after Fstl1 and Ifitm3 overexpression. COS7 cells were co-transfected with Fstl1, Ifitm3, and control vectors (mock) as indicated respectively. Overexpression of Ifitm3 increased Fstl1 protein in CM without affecting Fstl1 expression in COS7 cell lysates. Data show the mean ± SE ($n = 6$). *$p < 0.05$ versus Fstl1/mock. CM, conditioned medium.
polyI:C treatment, while Fstl1 protein levels were significantly increased in polyI:C ACM compared to that of the control ($p < 0.01$, Fig. 2c). These results suggest that Fstl1 is induced by polyI:C treatment in astrocytes but not in microglia, and thereby microglia may not play a role in the regulation of extracellular Fstl1 level.

We previously found that polyI:C-treated ACM impairs dendritic elongation of cultured hippocampal neurons [17]. Therefore, the role of Fstl1 in dendritic elongation was assessed using an RNA interference method. The effect of siRNA was confirmed by western blotting. When primary cultured astrocytes were transfected with control, Fstl1 #1 or #2 siRNA, the expression levels of Fstl1 in #1 or #2 siRNA were significantly decreased to 34% and 22% of control siRNA transfected cell (Additional file 1: Figure S1). Under this condition, Fstl1 protein levels in ACM were significantly increased by polyI:C treatment ($F(3,12) = 14.09$, $p < 0.01$, Fig. 3a). When astrocytes were transfected with either Fstl1 siRNA #1 or #2 to down-regulate Fstl1 expression, polyI:C failed to increase extracellular Fstl1 protein levels in ACM, and the levels were similar to those in control ACM ($F(3,12) = 14.09$, $p < 0.01$, Fig. 3a). To assess whether Fstl1 plays a negative role in neurite elongation, we measured dendrite length of primary cultured hippocampal neurons which were cultured with the ACM derived from either control or siRNA-treated astrocytes. PolyI:C-treated ACM impaired the dendritic elongation of cultured hippocampal neurons in control siRNA-transfected groups. This impairment was partially attenuated when astrocytes were transfected with either Fstl1 siRNA #1 or #2 ($F(3,174) = 92.53$, $p < 0.01$, Fig. 3b).

![Fig. 2 Changes in Ifitm3 and Fstl1 expression in polyI:C-treated astrocytes and microglia. a] Ifitm3 mRNA levels in polyI:C-treated astrocytes and microglia. Values indicate the means ± SE ($n = 4$). **$p < 0.01$ versus the respective control treatment. b] Fstl1 mRNA levels in polyI:C-treated astrocytes and microglia. Values indicate the means ± SE ($n = 4$). N.S., not significant. **$p < 0.01$ versus control treatment. c] Fstl1 protein levels in polyI:C ACM and polyI:C MCM. Values indicate the means ± SE ($n = 7$). **$p < 0.01$ versus control. ACM, astrocyte conditioned medium; MCM, microglia conditioned medium. N.D., not detectable.
Fig. 3 Effect of Fstl1 knockdown in astrocytes on polyI:C ACM-induced impairment of neuronal development. Astrocytes were transfected with control siRNA (CON), Fstl1 siRNA #1 (#1), or Fstl1 siRNA #2 (#2) before polyI:C or vehicle treatment, and then ACM and cell lysate samples were prepared 24 h after polyI:C treatment. 

**a** Representative western blot images of Fstl1 protein levels in ACM derived from siRNA-treated astrocytes. Values indicate the means ± SE (n = 4). **p < 0.01 versus control ACM, ##p < 0.01 versus control siRNA-treated polyI:C ACM.

**b** Effect of polyI:C ACM derived from Fstl1 knockdown astrocytes on MAP2-positive dendrite length of primary cultured neurons (DIV7). Neurons were cultured for 5 days (DIV2-7) with control ACM or polyI:C ACM derived from astrocytes transfected with control siRNA (CON) or Fstl1 siRNA (#1 or #2). Values indicate the means ± SE of more than three independent experiments (n = 28–59 neurons). **p < 0.01 versus control ACM, ##p < 0.01 versus control siRNA-treated polyI:C ACM. Scale bar, 50 μm
We further examined whether Fstl1 protein could mimic the above deleterious effect of polyI:C ACM. Addition of recombinant mouse Fstl1 protein to control ACM on DIV2 resulted in a concentration-dependent decrease in dendrite length of primary cultured neurons assayed on DIV7 \( F(3,203) = 22.08, p < 0.01, \text{Fig. 4a} \). The decrease in dendrite length induced by rmFstl1 treatment was 12% (50 nM), 32% (100 nM), and 35% (300 nM) compared to that treated with control ACM alone, and a significant decrease of dendritic length was observed at more than 100 nM rmFstl1 \( p < 0.01, \text{Fig. 4a} \). Of note, the addition of 300 nM rmFstl1 to normal culture medium on DIV2 had no effect on dendritic elongation of primary cultured hippocampal neurons assayed on DIV7 (Fig. 4b). rmFstl1 treatment had no effect on branched number of neurites and viability of neurons (Additional files 2 and 3: Figures S2 and S3). These results suggest that Fstl1 itself may not directly inhibit the dendritic elongation of neurons but interrupt neurite elongation by cooperating with some factors in ACM.

Finally, the in vivo expression of Fstl1 in the hippocampus 24 h after neonatal polyI:C treatment was analyzed by IHC. The expression of Fstl1 was hardly detected in vehicle-treated control mice under the same experimental conditions (Fig. 5a). Fstl1 immunofluorescence was clearly observed in the hippocampus of polyI:C-treated mice, and the signal coincided with GFAP, a marker for astrocytes (Fig. 5a). Approximately, 60% of astrocytes were positive for Fstl1 in the hippocampus of polyI:C-treated mice (Fig. 5b). The co-expression of Fstl1 with Ifitm3 in astrocyte was observed in the hippocampus of polyI:C-treated neonatal mice (Additional file 4: Figure S4). The expression level of Fstl1 in polyI:C-treated Ifitm3 KO mice was comparable to the level in polyI:C-treated WT mice (Additional file 5: Figure S5).

Discussion

We have previously demonstrated that mice received neonatal polyI:C treatment exhibit some characteristics of neurodevelopmental disorders including cognitive and emotional impairments in adulthood, which is accompanied by the decrease in spine density and dendrite complexity of pyramidal neurons in the frontal cortex [16, 17, 20]. PolyI:C treatment induces expression of several inflammation-related genes, and induction of these molecules plays a pivotal role in polyI:C-induced neuronal impairment. We have already demonstrated that Ifitm3 expression is increased by polyI:C treatment in astrocytes. Ifitm3 protein localizes to the early endosomes and reduces the endocytic activity of astrocytes, which may change the composition of the extracellular humoral factors. Ifitm3-mediated accumulation of humoral factors released from astrocytes is a determinant in polyI:C-induced neurodevelopmental impairment [17]. Mmp-3 is one of such humoral factors that contribute to the polyI:C-induced neuronal impairment [18].

In the present study, we demonstrated that extracellular Fstl1 level was also dramatically increased in
polyI:C-treated astrocytes. We confirmed that Fstl1 is upregulated in polyI:C-treated astrocytes and acts as a humoral factor to impair neurite elongation of cultured neurons. PolyI:C stimulates toll-like receptor 3 (TLR3) signaling, which leads to production of inflammatory cytokines [17, 21], while the expression level of Fstl1 mRNA increases in response to inflammatory cytokines such as IL-1, IL-6, and TNF-α [22, 23]. Therefore, polyI:C may upregulate Fstl1 mRNA levels through the production of inflammatory cytokines.

Fstl1 is a glycoprotein that is secreted in response to inflammatory signals. Lipopolysaccharide (LPS) increases Fstl1 expression [24, 25]. In the present study, we demonstrated that the extracellular level of Fstl1 in cultured astrocytes was increased by polyI:C treatment, but such increase was attenuated in Ifitm3 KO astrocytes. Moreover, co-expression of Fstl1 and Ifitm3 in COS7 cells significantly increased the extracellular level of Fstl1 compared to the level in COS7 cells only expressing Fstl1 but not Ifitm3. We speculate that polyI:C treatment may increase the extracellular level of Fstl1 through the inhibitory effect of Ifitm3 of endocytic activity [17]. An alternative explanation is that Ifitm3 may affect membrane vesicle trafficking and secretion in astrocytes. Because neither the mRNA expression level nor were the intracellular protein level of Fstl1 affected by Ifitm3 expression, regulation of Fstl1 expression may be independent on Ifitm3 expression. Ifitm3-independent expression of Fstl1 was also demonstrated in vivo. Although we attempted to measure extracellular Fstl1 in mice, it has not been detected yet because of analytical limitation. Further study is needed to directly show that the increased extracellular Fstl1 is responsible for the polyI:C-induced neuronal impairment.

**Fig. 5** In vivo expression of Fstl1 protein in PD7 neonates. Neonatal C57BL/6J mice were administered with a daily subcutaneous injection of saline (control) or polyI:C (5 mg/kg) between PD2 and PD6. a Hippocampal sections were isolated 24 h after the final drug treatment and Fstl1 (green) and GFAP (red, a marker for astrocytes) protein expressions were assessed by IHC. Scale bar, 10 μm. b Ratio of Fstl1- and GFAP-double positive cells versus GFAP positive cells was quantified. Values indicate the means ± SE of three independent experiments. *p < 0.05 versus control.
In addition to astrocytes, microglia are involved in the inflammation-related neuronal impairment [26, 27]. PolyI:C activates both astrocytes and microglia through activation of TLR3 [28, 29], which led us to hypothesize that Fstl1 expression would be increased not only in astrocytes but also in microglia, in response to polyI:C stimulation. The expression level of Ifitm3 mRNA was significantly increased by treatment with polyI:C both in cultured astrocytes and in cultured microglia. On the other hand, the expression level of Fstl1 mRNA was very limited in microglia compared to astrocytes, and not increased by polyI:C treatment in microglia. Furthermore, the extracellular Fstl1 protein of cultured microglia could not be detected either in the presence or absence of polyI:C treatment. These results suggest that the induction of Fstl1 in response to TLR3 activation by polyI:C may be a specific event in astrocytes, but not occur in microglia.

How does Fstl1 impair morphologic neuronal development? The role of Fstl1 is controversial because some findings suggest that Fstl1 functions as a pro-inflammatory cytokine [24, 30–32], but others suggest a role as an anti-inflammatory cytokines [25, 33, 34]. Fstl1 protects cells from apoptosis in heat failure through Fstl1 receptor [35, 36]. Some reports suggest that Fstl1 works as a scavenger by sequestering bone morphogenetic signaling pathway [37, 38]. The addition of both Fstl1 and ACM suppressed neurite outgrowth, but addition of Fstl1 alone did not. Co-treatment of Fstl1 with Bmp-4 and ACM suppressed neurite outgrowth, but addition of polyI:C treatment in microglia. Furthermore, the extracellular Fstl1 protein of cultured microglia could not be detected either in the presence or absence of polyI:C treatment. These results suggest that the induction of Fstl1 in response to TLR3 activation by polyI:C may be a specific event in astrocytes, but not occur in microglia.

Conclusions
From our findings, we conclude that the extracellular level of Fstl1 is regulated by Ifitm3 in astrocytes. However, Fstl1 itself may not directly inhibit the dendritic elongation of neurons but interrupt neurite elongation by cooperating with some factors in ACM.

Additional files

Additional file 1: Figure S1. Validation of Fstl1 knockdown, related to Fig. 3. Culture astrocytes were transfected with siRNA targeting for Fstl1 or control siRNA. Western blotting was performed with indicated antibodies. (PPTX 66 kb)

Additional file 2: Figure S2. Effect of rFstl1 treatment on neurite branch, related to Fig. 4. Neurons were treated with indicated concentration of rmFstl1 or vehicle. Branched number of neurites was counted. Values indicate the means ± SE (n = 30–38). (PPTX 26 kb)

Additional file 3: Figure S3. Effect of rFstl1 treatment on neurite branch, related to Fig. 4. Neurons were treated with indicated concentration of rmFstl1 or vehicle. Branched number of neurites was counted. Values indicate the means ± SE (n = 30–38). (PPTX 26 kb)

Additional file 4: Figure S4. Co-expression of Fstl1 with Ifitm3 in the hippocampus of polyI:C-treated neonatal mice, related to Fig. 5. Hippocampal sections prepared from mice treated with vehicle or polyI:C were immunostained with indicated antibodies. Scale bar, 20 μm. (PPTX 2707 kb)

Additional file 5: Figure S5. Expression of Fstl1 in polyI:C-treated Ifitm3 KO mice, related to Fig. 5. Hippocampal brain slices prepared from vehicle- or polyI:C-treated Ifitm3 KO mice were immunostained with indicated antibodies. Scale bar, 20 μm. (PPTX 46 kb)

Additional file 6: Figure S6. Effect of rFstl1 treatment on neurite branch, related to Fig. 4. Neurons were treated with indicated concentration of rmFstl1 or vehicle. Branched number of neurites was counted. Values indicate the means ± SE of three independent experiments. Scale bar, 20 μm. (PPTX 120 kb)

Abbreviations
ACM: Astrocyte conditioned medium; Bmp-4: Bone morphogenetic protein-4; CNS: Central nervous system; DIP2: Disco-interacting protein 2; Fstl1: Follistatin-like 1; GFAP: Glial fibrillary acidic protein; Ifitm3: Interferon-induced transmembrane protein 3; IHC: Immunohistochemistry; IL-6: Interleukin-6; LPS: Lipopolysaccharide; MCM: Microglia-conditioned medium; Mmp3: Matrix metalloproteinase 3; PolyI:C: Polyriboinosinic-polyribocytidylic acid; TLR3: Toll-like receptor 3; TNF-α: Tumor necrosis factor-α

Acknowledgements
We thank Dr. Ulrike C. Lange, David J. Adams, and Asim Surani for providing the Ifitm3 KO mouse. We also thank all members of Yamada Lab for their helpful discussions and support of this work.

Funding
This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant-in-Aid for Scientific Research (B) 17H04033) to K.Y., 17H04052 to T. Nabetama, 17H02220 to T. Nagai, Grant-in-Aid for Challenging Exploratory Research 16K15201 to K.Y., 17K19483 to T. Nagai, Grant-in-Aid for Scientific Research on Innovative Areas 24111518 to K.Y., Grant-in-Aid for Young Scientists (B) 16K21080 to N.I. and the Private University Research Branding Project from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), the Astellas Foundation for Research on Metabolic Disorders, The Hori Science and Arts Foundation, Grant for Biomedical Research from Smoking Research Foundation (SRF), the Uehara Memorial Foundation and partially supported by the Strategic Research Program for Brain Sciences, and Research on Regulatory Science of Pharmaceuticals and Medical Devices from Japan Agency for Medical Research and Development, AMED. The Pharmacological Research Foundation, Tokyo.
Availability of data and materials
The dataset used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SY, TNagai, NI, and KY designed the study. SY, TNagai, and NI performed experiments and analyzed the data. SY, TNagai, DI, AN, TNabeshima, and KY analyzed and interpreted the data. SY, NI, TNagai, TNabeshima, and KY wrote the manuscript. All of the authors discussed the results and agreed on the content of the manuscript.

Ethics approval
This study was approved by the Institutional Animal Care and Use Committee of Nagoya University (Approval No. 30248). Animals were handled in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Nagoya University.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Turumacho, Showa-ku, Nagoya, Aichi 466-8550, Japan. 2Department of Chemical Pharmacology, Faculty of Pharmaceutical Science, Meijo University, 150 Yagotoyama, Tenpaku-ku, Nagoya, Japan. 3Faculty of Agriculture and Life Science, Hiroshima University, 3 Bunkyo-cho, Hiroaki, Aomori 036-8561, Japan. 4Advanced Diagnostic System Research Laboratory, Fujita Health University, Graduate School of Health Science and Aino University, 1-98 Dengakukagubu, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.

Received: 7 June 2018 Accepted: 12 October 2018
Published online: 22 October 2018

References
1. Luo Y, He H, Zhang M, Huang X, Zhang J, Zhou Y, Liu X, Fan N. Elevated serum levels of TNF-alpha, IL-6 and IL-18 in chronic schizophrenic patients. Schizophr Res. 2014;155S:6–7.
2. Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 2016;239:85–91.
3. Schmidt FM, Schroder T, Kirkby KC, Sander C, Suslow T, Holdt LM, Teupser D, Hegerl U, Himmerich H. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 2016;239:85–91.
4. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, Babulas VP, Susser ES. Serologic evidence of prenatal infection in the etiology of schizophrenia. Arch Gen Psychiatry. 2004;61:774–80.
5. Khandaker GM, Zimbrown J, Dalmann C, Lewis G, Johns PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. 2012;139:61–8.
6. Khandaker GM, Zimbrown J, Lewis G, Johns PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med. 2013;43:239–57.
7. Ibá D, Yamada K. Therapeutic targets for neurodevelopmental disorders emerging from animal models with perinatal immune activation. Int J Mol Sci. 2015;16:2818–29.
8. Koyama Y. Functional alterations of astrocytes in mental disorders: pharmacological significance as a drug target. Front Cell Neurosci. 2015;9:261.
9. Bailey CC, Zhong G, Huang IC, Farzan M. FIMT-family proteins: the cell’s first line of antiviral defense. Annu Rev Virol. 2014;1:261–83.
10. Chesarino NM, McMichael TM, Yount JS. Regulation of the trafficking and antiviral activity of FIMT3 by post-translational modifications. Future Microbiol. 2014;9:1151–63.
11. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Karle L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palote A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, Gen II, Investigators M, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. FIMT3 restricts the morbidity and mortality associated with influenza. Nature. 2012;484:519–23.
12. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikjig E, Adams DJ, Xaver RJ, Farzan M, Ellelge SJ. The FIMT proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009;139:243–54.
13. Yamada S, Yamada K. Matrix metalloproteinase-9 is a possible mediator of neurodevelopmental impairment due to polyC-induced innate immune activation of astrocytes. Brain Behav Immun. 2014;38:273–82.
14. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradlely A, Surani MA. Normal germ line establishment in mice carrying a deletion of the Ifttm1/Fragilis gene family cluster. Mol Cell Biol. 2008;28:4686–96.
15. Ibá D, Nagai T, Koike H, Kitahara Y, Mizoguchi H, Hada K, Nitta A, Yoneda Y, Yamada K. Matrix metalloproteinase-9 is a possible mediator of neurodevelopmental impairment due to polyC-induced innate immune activation of astrocytes. Brain Behav Immun. 2014;38:273–82.
16. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradlely A, Surani MA. Normal germ line establishment in mice carrying a deletion of the Ifttm1/Fragilis gene family cluster. Mol Cell Biol. 2008;28:4686–96.
17. Ibi D, Nagai T, Kitahara Y, Mizoguchi H, Kogo H, Shiakai T, Kishima K, Kamei N, Noda Y, Nitta A, Nabeshima T, Yoneda Y, Yamada K. Neocortical polyC treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci Res. 2009;64:297–305.
18. Ibi D, Nagai T, Nakajima A, Mizoguchi H, Kawase T, Tsuibo D, Kano S, Sato Y, Hayakawa M, Lange UC, Adams DJ, Surani MA, Sato S, Sawada K, Kalbuchi K, Nabeshima T, Yamada K. Astroglial FIMT3 mediates neuronal impairments following neonatal immune challenge in mice. Glia. 2013;61:679–93.
19. Yamada S, Nagai T, Nakai T, Ibi D, Nakajima A, Yamada K. Matrix metalloproteinase-9 is a possible mediator of neurodevelopmental impairment due to polyC-induced innate immune activation of astrocytes. Brain Behav Immun. 2014;38:273–82.
20. Sobue A, Ikot N, Nagai T, Shan W, Hada K, Nakajima A, Murakami Y, Moura I, Yamamoto Y, Nabeshima T, Sato Y, Yamada K. Astroglial major histocompatibility complex class I following immune activation leads to behavioral and neuropathological changes. Glia. 2018;66:1039–52.
21. Clutter SD, Wilson DC, Marinov AD, Hirsch R. Follistatin-like protein 1 suppresses arthritis by up-regulating IFN-gamma. J Immunol. 2019;192:2334–9.
31. Ni S, Miao K, Zhou X, Xu N, Li C, Zhu R, Sun R, Wang Y. The involvement of follistatin-like protein 1 in osteoarthritis by elevating NF-kappaB-mediated inflammatory cytokines and enhancing fibroblast like synoviocyte proliferation. Arthritis Res Ther. 2015;17:91.

32. Zhang ZM, Zhang AR, Xu M, Lou J, Qiu WQ. TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in mycobacterium tuberculosis-infected macrophages. Exp Cell Res. 2017;352:213–21.

33. Li D, Wang Y, Xu N, Wei Q, Wu M, Li X, Zheng P, Sun S, Jin Y, Zhang G, Liao R, Zhang P. Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Res Ther. 2011;13:R17.

34. Hayakawa S, Ohashi K, Shibata R, Kataoka Y, Miyabe M, Enomoto T, Joki Y, Shimizu Y, Kambara T, Uemura Y, Yasuda D, Ogawa H, Matsumo K, Hiramatsu-ito M, van den Hoff MJ, Walsh K, Murohara T, Ouchi N. Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal nephrectomy model. J Am Soc Nephrol. 2015;26:636–46.

35. Ouchi N, Asaumi Y, Ohashi K, Higuchi A, Sono-Romanelli S, Oshima Y, Walsh K. DIP2A functions as a FSTL1 receptor. J Biol Chem. 2010;285:7217–34.

36. Tanaka M, Murakami K, Ozaki S, Imura Y, Tong XP, Watanabe T, Sawaki T, Kawanami T, Kawabata D, Fujii T, Usui T, Masaki Y, Fukushima T, Jin ZX, Umehara H, Mimori T. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1--analysis of their binding with TGF-beta superfamily proteins. FEBS J. 2010;277:4278–89.

37. Geng Y, Dong Y, Yu M, Zhang L, Yan X, Sun J, Qiao L, Geng H, Nakajima M, Furuchi T, Ikegawa S, Gao X, Chen YG, Jiang D, Ning W. Follistatin-like 1 (Fst1l) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proc Natl Acad Sci U S A. 2011;108:7058–63.

38. Sylva M, Li VS, Buffing AA, van Es JH, van den Born M, van der Velden S, Gunst Q, Koolstra JH, Moorman AF, Clevers H, van den Hoff MJ. The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis. PLoS One. 2011;6:e22616.

39. Xu J, Qi X, Gong J, Yu M, Zhang F, Sha H, Gao X. Fstl1 antagonizes BMP signaling and regulates urogenital development. PLoS One. 2012;7:e32554.

40. Li KC, Zhang FX, Li CL, Wang F, Yu MY, Zhong YQ, Zhang KH, Lu YJ, Wang Q, Ma XL, Yao JR, Wang YJ, Lin LB, Han M, Zhang YQ, Kuner R, Xiao HS, Bao L, Gao X, Zhang X. Follistatin-like 1 suppresses sensory afferent transmission by activating Na+, K+-ATPase. Neuron. 2011;69:974–87.

41. Sundaram GM, Common JE, Gopal FE, Srikantha S, Lakshman K, Lunny DP, Lim TC, Tanawde V, Lane EB, Sampath P. ‘See-saw’ expression of microRNA-198 and FSTL1 from a single transcript in wound healing. Nature. 2013;495:103–6.

42. Hansen T, Olsen L, Lindov M, Jakobsen KD, Ulum H, Jonssen E, Andreassen OA, Djurovic S, Melle I, Agartz I, Hall H, Timm S, Wang AG, Werge T. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One. 2007;2:e673.

43. Beveridge NJ, Cairns MJ. MicroRNA dysregulation in schizophrenia. Neurobiol Dis. 2012;46:263–71.